Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients
Phase II Randomized, Multicenter, Crossover Clinical Trial for Administration of Exemestane vs. Anastrozole as First Line Treatment for Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Sponsor: Pfizer
Listed as NCT00128843, this PHASE2 trial focuses on Breast Cancer and remains completed. Sponsored by Pfizer, it has been updated 9 times since 2001, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Apr 2023 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Mar 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Mar 2019 [monthly]
Completed PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Apr 2018 [monthly]
Completed PHASE2
First recorded
Aug 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
- Spanish Breast Cancer Research Group
For direct contact, visit the study record on ClinicalTrials.gov .